A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure Divided into Two Stages: Stage One Open-Label, Sequential Dose-Escalation Cohorts and Stage Two Randomized, Double-Blind, Placebo-Control, Parallel Cohorts (CUPID)

ID Number 08-0844

Principal Investigator(s)
Jill Kalman

Department(s) or Division(s)


The study is divided into 2 parts. In the first part, the safety of the gene transfer agent MYDICAR® will be evaluated. In the second part, the ability of MYDICAR® to improve heart function will be studied. ClinicalTrials.gov Identifier: NCT00454818

Contact Information
Cris Surach

Recruiting Patients: No